EPO Biosimilar, CDMO Sales Continue to Rise
[by Yu, Suin] Huons Group's biologics-specialized affiliated company PanGen Biotech announced on April 2nd that it has signed a contract manufacturing organization (CMO) agreement with CHA Biotech Group's CHA Vaccine Institute.
CHA Vaccine Institute is a KOSDAQ-listed company that develops next-generation vaccines and immunotherapy drugs using its proprietary immune-boosting platform technology. CHA Vaccine Institute has outsourced its project worth KRW 1.9 billion to 바카라 꽁 머니. The key terms of the agreement are not disclosed due to a confidentiality agreement signed between the two companies.
바카라 꽁 머니 provides contract development and manufacturing organization (CDMO) business for biopharmaceuticals and also manufactures and sells biosimilars based on its expertise in developing original cell lines and establishing processes for biopharmaceutical production.
CEO of 바카라 꽁 머니, Yoon Jae-seung says, "CHA Vaccine Institute and 바카라 꽁 머니 have been collaborating since the beginning of our businesses, including joint development and 바카라 꽁 머니's CDMO contract for biopharmaceuticals. This CMO contract is another collaboration, and we will continue to work closely with CHA Vaccine Institute for mutual growth."
바카라 꽁 머니 was incorporated into Huons Group in December 2024. In 2024, 바카라 꽁 머니 turned into a surplus due to strong overseas sales of Erythropoietin (EPO) biosimilar and rising sales in CDMO business. In 2025, 바카라 꽁 머니 plans to further strengthen its competitiveness as a global biopharmaceutical development company with Huons Group.